Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more
Entero Therapeutics, Inc. (ENTO) - Net Assets
Latest net assets as of September 2025: $89.56 Million USD
Based on the latest financial reports, Entero Therapeutics, Inc. (ENTO) has net assets worth $89.56 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($135.37 Million) and total liabilities ($45.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $89.56 Million |
| % of Total Assets | 66.16% |
| Annual Growth Rate | 252.92% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1601957.87 |
Entero Therapeutics, Inc. - Net Assets Trend (2013–2024)
This chart illustrates how Entero Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual net assets of Entero Therapeutics, Inc. from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $57.80 Million | +1504.37% |
| 2023-12-31 | $3.60 Million | +31.39% |
| 2022-12-31 | $2.74 Million | +135.06% |
| 2021-12-31 | $-7.82 Million | -196.19% |
| 2020-12-31 | $-2.64 Million | -157.19% |
| 2019-12-31 | $4.62 Million | +3.20% |
| 2018-12-31 | $4.47 Million | +63.78% |
| 2017-12-31 | $2.73 Million | -14.98% |
| 2016-12-31 | $3.21 Million | +188.52% |
| 2015-12-31 | $-3.63 Million | -237.24% |
| 2014-12-31 | $2.64 Million | +4844035.53% |
| 2013-12-31 | $54.60 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Entero Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20238699350.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $475.00 | 0.00% |
| Other Components | $260.19 Million | 450.13% |
| Total Equity | $57.80 Million | 100.00% |
Entero Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Entero Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
G3 Global Bhd
KLSE:7184
|
$4.22 Million |
|
Platina Resources Limited
PINK:PTNUF
|
$4.22 Million |
|
YOLO GROUP S.P.A. O.N.
F:X2Y
|
$4.23 Million |
|
Signet Industries Limited
NSE:SIGIND
|
$4.23 Million |
|
Hagag Group
TA:HGG
|
$4.22 Million |
|
Tecom Co Ltd
TW:2321
|
$4.22 Million |
|
Alchemy Resources Ltd
AU:ALY
|
$4.22 Million |
|
Gullewa Ltd
AU:GUL
|
$4.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entero Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,602,929 to 57,804,362, a change of 54,201,433 (1504.4%).
- Net loss of 18,059,336 reduced equity.
- New share issuances of 6,225,891 increased equity.
- Other factors increased equity by 66,034,878.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.06 Million | -31.24% |
| Share Issuances | $6.23 Million | +10.77% |
| Other Changes | $66.03 Million | +114.24% |
| Total Change | $- | 1504.37% |
Book Value vs Market Value Analysis
This analysis compares Entero Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.17x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 12.15x to 0.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.23 | $2.85 | x |
| 2014-12-31 | $11364.17 | $2.85 | x |
| 2015-12-31 | $-15596.07 | $2.85 | x |
| 2016-12-31 | $20745.09 | $2.85 | x |
| 2017-12-31 | $10794.10 | $2.85 | x |
| 2018-12-31 | $12170.49 | $2.85 | x |
| 2019-12-31 | $8647.50 | $2.85 | x |
| 2020-12-31 | $-3900.29 | $2.85 | x |
| 2021-12-31 | $-3680.43 | $2.85 | x |
| 2022-12-31 | $76.36 | $2.85 | x |
| 2023-12-31 | $10.71 | $2.85 | x |
| 2024-12-31 | $16.83 | $2.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entero Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.48x
- Recent ROE (-31.24%) is above the historical average (-370.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -1857.22% | 0.00% | 0.00x | 18.20x | $-1.02K |
| 2014 | -89.42% | 0.00% | 0.00x | 2.49x | $-2.63 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.57 Million |
| 2016 | -454.14% | 0.00% | 0.00x | 2.10x | $-14.91 Million |
| 2017 | -406.21% | 0.00% | 0.00x | 2.40x | $-11.37 Million |
| 2018 | -302.50% | 0.00% | 0.00x | 1.67x | $-13.98 Million |
| 2019 | -328.72% | 0.00% | 0.00x | 1.93x | $-15.64 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.41 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.76 Million |
| 2022 | -533.51% | 0.00% | 0.00x | 1.98x | $-14.90 Million |
| 2023 | -438.39% | 0.00% | 0.00x | 1.91x | $-16.16 Million |
| 2024 | -31.24% | 0.00% | 0.00x | 1.48x | $-23.84 Million |
Industry Comparison
This section compares Entero Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entero Therapeutics, Inc. (ENTO) | $89.56 Million | -1857.22% | 0.51x | $4.22 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |